Literature DB >> 18216243

Molecular switch for CLC-K Cl- channel block/activation: optimal pharmacophoric requirements towards high-affinity ligands.

Antonella Liantonio1, Alessandra Picollo, Giuseppe Carbonara, Giuseppe Fracchiolla, Paolo Tortorella, Fulvio Loiodice, Antonio Laghezza, Elena Babini, Giovanni Zifarelli, Michael Pusch, Diana Conte Camerino.   

Abstract

ClC-Ka and ClC-Kb Cl(-) channels are pivotal for renal salt reabsorption and water balance. There is growing interest in identifying ligands that allow pharmacological interventions aimed to modulate their activity. Starting from available ligands, we followed a rational chemical strategy, accompanied by computational modeling and electrophysiological techniques, to identify the molecular requisites for binding to a blocking or to an activating binding site on ClC-Ka. The major molecular determinant that distinguishes activators from blockers is the level of planarity of the aromatic portions of the molecules: only molecules with perfectly coplanar aromatic groups display potentiating activity. Combining several molecular features of various CLC-K ligands, we discovered that phenyl-benzofuran carboxylic acid derivatives yield the most potent ClC-Ka inhibitors so far described (affinity <10 microM). The increase in affinity compared with 3-phenyl-2-p-chlorophenoxy-propionic acid (3-phenyl-CPP) stems primarily from the conformational constraint provided by the phenyl-benzofuran ring. Several other key structural elements for high blocking potency were identified through a detailed structure-activity relationship study. Surprisingly, some benzofuran-based drugs inhibit ClC-Kb with a similar affinity of <10 microM, thus representing the first inhibitors for this CLC-K isoform identified so far. Based on our data, we established a pharmacophore model that will be useful for the development of drugs targeting CLC-K channels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18216243      PMCID: PMC2234145          DOI: 10.1073/pnas.0708977105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

Review 1.  CLC-K channels: if the drug fits, use it.

Authors:  Peying Fong
Journal:  EMBO Rep       Date:  2004-06       Impact factor: 8.807

2.  Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure.

Authors:  R Birkenhäger; E Otto; M J Schürmann; M Vollmer; E M Ruf; I Maier-Lutz; F Beekmann; A Fekete; H Omran; D Feldmann; D V Milford; N Jeck; M Konrad; D Landau; N V Knoers; C Antignac; R Sudbrak; A Kispert; F Hildebrandt
Journal:  Nat Genet       Date:  2001-11       Impact factor: 38.330

3.  Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome.

Authors:  Martin Konrad; Martin Vollmer; Henny H Lemmink; Lambertus P W J VAN DEN Heuvel; Nikola Jeck; Rosa Vargas-Poussou; Alicia Lakings; Rainer Ruf; Georges Deschênes; Corinne Antignac; Lisa Guay-Woodford; Nine V A M Knoers; Hannsjörg W Seyberth; Delphine Feldmann; Friedhelm Hildebrandt
Journal:  J Am Soc Nephrol       Date:  2000-08       Impact factor: 10.121

4.  Barttin is a Cl- channel beta-subunit crucial for renal Cl- reabsorption and inner ear K+ secretion.

Authors:  R Estévez; T Boettger; V Stein; R Birkenhäger; E Otto; F Hildebrandt; T J Jentsch
Journal:  Nature       Date:  2001-11-29       Impact factor: 49.962

5.  Impaired solute accumulation in inner medulla of Clcnk1-/- mice kidney.

Authors:  N Akizuki; S Uchida; S Sasaki; F Marumo
Journal:  Am J Physiol Renal Physiol       Date:  2001-01

6.  Activating mutation of the renal epithelial chloride channel ClC-Kb predisposing to hypertension.

Authors:  Nikola Jeck; Siegfried Waldegger; Angelika Lampert; Christoph Boehmer; Petra Waldegger; Philipp A Lang; Bernd Wissinger; Björn Friedrich; Teut Risler; Robert Moehle; Undine E Lang; Peter Zill; Brigitta Bondy; Elke Schaeffeler; Stephen Asante-Poku; Hannsjörg Seyberth; Matthias Schwab; Florian Lang
Journal:  Hypertension       Date:  2004-05-17       Impact factor: 10.190

7.  Barttin increases surface expression and changes current properties of ClC-K channels.

Authors:  Siegfried Waldegger; Nikola Jeck; Petra Barth; Melanie Peters; Helga Vitzthum; Konrad Wolf; Armin Kurtz; Martin Konrad; Hannsjörg W Seyberth
Journal:  Pflugers Arch       Date:  2002-04-09       Impact factor: 3.657

8.  Investigations of pharmacologic properties of the renal CLC-K1 chloride channel co-expressed with barttin by the use of 2-(p-Chlorophenoxy)propionic acid derivatives and other structurally unrelated chloride channels blockers.

Authors:  Antonella Liantonio; Michael Pusch; Alessandra Picollo; Patrizia Guida; Annamaria De Luca; Sabata Pierno; Giuseppe Fracchiolla; Fulvio Loiodice; Paolo Tortorella; Diana Conte Camerino
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

9.  Molecular requisites for drug binding to muscle CLC-1 and renal CLC-K channel revealed by the use of phenoxy-alkyl derivatives of 2-(p-chlorophenoxy)propionic acid.

Authors:  Antonella Liantonio; Alessio Accardi; Giuseppe Carbonara; Giuseppe Fracchiolla; Fulvio Loiodice; Paolo Tortorella; Sonia Traverso; Patrizia Guida; Sabata Pierno; Annamaria De Luca; Diana Conte Camerino; Michael Pusch
Journal:  Mol Pharmacol       Date:  2002-08       Impact factor: 4.436

10.  Mechanism of interaction of niflumic acid with heterologously expressed kidney CLC-K chloride channels.

Authors:  Alessandra Picollo; Antonella Liantonio; Elena Babini; Diana Conte Camerino; Michael Pusch
Journal:  J Membr Biol       Date:  2007-07-21       Impact factor: 1.843

View more
  24 in total

1.  Identification of sites responsible for the potentiating effect of niflumic acid on ClC-Ka kidney chloride channels.

Authors:  G Zifarelli; A Liantonio; A Gradogna; A Picollo; G Gramegna; M De Bellis; A R Murgia; E Babini; D Conte Camerino; M Pusch
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  Chloride channels as drug targets.

Authors:  Alan S Verkman; Luis J V Galietta
Journal:  Nat Rev Drug Discov       Date:  2008-01-19       Impact factor: 84.694

3.  Statins and fibrate target ClC-1 - from side effects to CLC pharmacology.

Authors:  Anselm A Zdebik
Journal:  Br J Pharmacol       Date:  2009-04       Impact factor: 8.739

Review 4.  Ion channels in renal disease.

Authors:  Ivana Y Kuo; Barbara E Ehrlich
Journal:  Chem Rev       Date:  2012-07-18       Impact factor: 60.622

5.  A selective class of inhibitors for the CLC-Ka chloride ion channel.

Authors:  Anna K Koster; Chase A P Wood; Rhiannon Thomas-Tran; Tanmay S Chavan; Jonas Almqvist; Kee-Hyun Choi; J Du Bois; Merritt Maduke
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-18       Impact factor: 11.205

6.  Taming unruly chloride channel inhibitors with rational design.

Authors:  Rebecka J Sepela; Jon T Sack
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-07       Impact factor: 11.205

7.  Niflumic acid alters gating of HCN2 pacemaker channels by interaction with the outer region of S4 voltage sensing domains.

Authors:  Lan Cheng; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2009-02-13       Impact factor: 4.436

8.  A regulatory calcium-binding site at the subunit interface of CLC-K kidney chloride channels.

Authors:  Antonella Gradogna; Elena Babini; Alessandra Picollo; Michael Pusch
Journal:  J Gen Physiol       Date:  2010-09       Impact factor: 4.086

Review 9.  Flufenamic acid as an ion channel modulator.

Authors:  Romain Guinamard; Christophe Simard; Christopher Del Negro
Journal:  Pharmacol Ther       Date:  2013-01-25       Impact factor: 12.310

Review 10.  Novel diuretic targets.

Authors:  Jerod S Denton; Alan C Pao; Merritt Maduke
Journal:  Am J Physiol Renal Physiol       Date:  2013-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.